Cirrhosis
Conditions
Keywords
liver transplant, end-stage liver disease, cirrhosis
Brief summary
The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.
Detailed description
This study is looking at using a noninvasive test called a reactive hyperemia peripheral artery tonometry (RH-PAT) to check endothelial dysfunction. Endothelial dysfunction is thought to be an indication of future heart disease or metabolic disorders. Adiponectin is a hormone associated with heart disease. Apolipoprotein levels, are established risk factors for coronary artery disease in the general population. Our group would like to see if there is a link between endothelial function, adiponectin, apolipoprotein levels and posttransplant heart disease complications. The study would be taking these results to find new clinical procedures for patients that are at potentially higher risk of heart problems during and after their liver transplant procedure.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Greater than or equal to 21 years of age. * Cirrhotic end-stage liver disease * Pre-transplant
Exclusion criteria
* Dialysis shunt * non-cirrhotic liver disease * fulminant hepatic failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endothelial dysfunction in cirrhotic liver transplant candidates up to one year after transplant. | one year posttransplant | Endothelial function testing will be performed by reactive hyperemia peripheral artery tonometry in consecutive patients ≥21 years old awaiting liver transplantation and repeated at 3 weeks, 4 months and 1 year post transplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic abnormalities and cardiovascular disease by endothelial dysfunction and blood testing up to one year pre-transplant | 1 year posttransplant | Endothelial dysfunction testing, apolipoproteins and adiponectin levels will be performed prior to liver transplantation and repeated at 3 weeks (endothelial dysfunction only), 4 months and 1 year post transplantation. Pre transplant results will be analyzed for association with perioperative cardiovascular events. In addition, post transplant endothelial dysfunction results (and the delta change) along with adiponectin levels will be analyzed for cardiovascular event endpoints by 1 year post transplant. |
Countries
United States
Outcome results
None listed